Treatment With Ursodeoxycholic Acid Is Associated With Weight Gain in Patients With Primary Biliary Cirrhosis
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Background Ursodeoxycholic acid (UDCA) is the established treatment of primary biliary cirrhosis (PBC) and is a safe and well-tolerated medication. Nevertheless, patients often anecdotally complain of weight gain while on this drug. Goals We compared weight changes in patients treated with UDCA and those on placebo to characterize this potential side effect. Study One-hundred eighty patients with PBC who were enrolled into a randomized, controlled trial received either UDCA (13-15 mg/kg/d) or an identical placebo. Changes from baseline weight were calculated at 12, 24, 36, and 48 months. Other markers of disease activity, including liver biochemistries, serum lipids, histologic stage, and Mayo Risk Score were evaluated in both groups. Results The proportion of patients who gained weight during the first 12 months of therapy was significantly greater in the UDCA than placebo group (67/86 [78%] versus 43/73 [57%] respectively, P = 0.005). Patients in the UDCA group gained an average of 3.6 +/- 6.5% kg (2.2 +/- 5.1 kg) which was significantly greater than the average of 0.6 +/- 6.9% kg (0.6 +/- 4.9 kg) gained in the placebo group (P = 0.04). The biggest change in weight occurred in the first 12 months of treatment (P Conclusion UDCA treatment in patients with PBC is associated with a significant weight gain that occurs in the first 12 months of treatment, persists for the duration of treatment, and occurs independent of baseline BMI. Discussions with PBC patients beginning UDCA…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A 5-pound weight gain over the first year of therapy has been reported and is not progressive.(155)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [155]
Citations
Cites
Cytokines in Alcoholic and Nonalcoholic Steatohepatitis
Tilg, H., & Diehl, A. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432007 · Cited by 948 · cited 1×
“The role of cytokines in patients with PBC is not well understood, but TNF production is thought to be involved in many types of liver injury and may be responsible for initiating a complex interaction between other cytokines that causes hepatocyte death.(21) In a previous study involving this same patient population,…”
BackgroundThe presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487 · cited 2×
“The clinical characteristics of these patients, as well as the results of this study have been published elsewhere.(12) Patients included in the study were those in whom the diagnosis of PBC was based on the following criteria: (1) a chronic cholestatic liver disease of at least 6 months’ duration; (2) a serum alkalin…”
MethodSelf-citationRoll, J., Boyer, J. L., Barry, D., & Klatskin, G. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301063080101 · Cited by 417 · cited 1×
“The most frequent complaints at presentation typically include fatigue and pruritus,(1) although as many as one-half of patients are clinically asymptomatic at presentation and their disease is discovered based on an incidental discovery of an elevated serum alkaline phosphatase level.(2)”
BackgroundLong‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510290301 · Cited by 234 · cited 1×
“UDCA is a well-tolerated drug, and patients rarely report side effects.(17) In a previously published study, we found that only 12% of patients reported side effects, which included hypertension, creatinine elevation, thrombocytopenia, leukopenia, nausea/vomiting, diarrhea, fever, and rash, but these occurred in the s…”
ResultSelf-citationAngulo, P., Lindor, K. D., Therneau, T. M., Jorgensen, R. A., Malinchoc, M., Kamath, P. S., & Dickson, E. R. (1999) · Liver International · doi:10.1111/j.1478-3231.1999.tb00020.x · Cited by 203 · cited 1×
“These symptoms were unusual, and none of them resulted in discontinuation of the drug.(13,14) The effects of UDCA on weight have not been described, but have been questioned by some patients.”
BackgroundSelf-citationLangstein, H. N., & Norton, J. A. (1991) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30457-x · Cited by 170
Angulo, P., Dickson, E. R., Therneau, T. M., Jorgensen, R. A., Smith, C., DeSotel, C. K., Lange, S. M., Anderson, M. L., Mahoney, D. W., & Lindor, K. D. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80136-6 · Cited by 134 · cited 1×
“These symptoms were unusual, and none of them resulted in discontinuation of the drug.(13,14) The effects of UDCA on weight have not been described, but have been questioned by some patients.”
BackgroundSelf-citationJourney from cachexia to obesity by TNF
Argilés, J. M., López‐Soriano, J., Busquets, S., & López‐Soriano, F. J. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.10.9271359 · Cited by 131 · cited 1×
“While increased levels of these proteins has been linked to cachectic states, recent literature describes a possible role in obesity.(18) The meaning of this modest weight gain is unclear.”
BackgroundPRIMARY BILIARY CIRRHOSIS AND CŒLIAC DISEASE
Logan, R. F., Ferguson, A., Finlayson, N. D. C., & Weir, D. G. (1978) · The Lancet · doi:10.1016/s0140-6736(78)90480-4 · Cited by 130
Research works printed but not linked: 3
- DiBaise, 1998, Am J Gastroenterol, 93, 2226
- Ginn, 1992, West J Med, 156, 547
- Behr, 1986, Am J Gastroenterol, 81, 796
Cited by
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“A 5-pound weight gain over the first year of therapy has been reported and is not progressive.(155) Loose stools and/or thinning of the hair have also been reported infrequently.”
BackgroundSelf-citationDiagnosis and Management of Cirrhosis and Its Complications: A Review
Tapper, E. B., & Parikh, N. D. (2023) · JAMA · doi:10.1001/jama.2023.5997 · Cited by 392
Ursodeoxycholic acid for primary biliary cirrhosis
Rudic, J. S., Poropat, G., Krstic, M. N., Bjelakovic, G., & Gluud, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000551.pub3 · Cited by 270
Hirschfield, G. M., & Heathcote, E. J. (2010) · Evidence‐Based Gastroenterology and Hepatology · doi:10.1002/9781444314403.ch32 · Cited by 261
Metadata
- Authors
- Siegel, J. L., Jorgensen, R., Angulo, P., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Lindor, Keith D.
- ORCID
- Lindor, Keith D.
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2003-08
- Volume
- 37
- Issue
- 2
- Pages
- 183-185
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2054103320
- Cited by
- 40
- References
- 23
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 3 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 2 · 2012: 4
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- ursodeoxycholic acid, primary biliary cirrhosis, weight gain, adverse drug reactions, body mass index, disease activity, Mayo risk score, serum lipids
- MeSH terms
- Cholagogues and Choleretics, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Ursodeoxycholic Acid, Weight Gain, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment With Ursodeoxycholic Acid Is Associated With Weight Gain in Patients With Primary Biliary Cirrhosis. https://app.cochat.ai/papers/10.1097/00004836-200308000-00018
- The paper
- Siegel, J. L., Jorgensen, R., Angulo, P., & Lindor, K. D. (2003). Treatment With Ursodeoxycholic Acid Is Associated With Weight Gain in Patients With Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology. https://doi.org/10.1097/00004836-200308000-00018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.